Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Phase 2

Recruiting

Conditions: Hypercalcemia, Idiopathic, of Infancy
Hypercalciuric Hypercalcemia
Hypercalciuria
Idiopathic Infantile Hypercalcaemia - Severe Form
Genetic Disease
Idiopathic Infantile Hypercalcemia - Mild Form

Interventions: Drug: Rifampin

First Posted Date: 2017-10-04

Last Posted Date: 2024-08-07

Lead Sponsor: Children's Hospital of Philadelphia

Target Recruit Count: 60

Registration Number: NCT03301038

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers: Asian, Non-Asian

Interventions: Drug: BGB-3111 (Arm A)
Drug: BGB-3111 (Arm B)
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2017-10-04

Last Posted Date: 2019-11-01

Lead Sponsor: BeiGene

Target Recruit Count: 40

Registration Number: NCT03301181

Locations: 🇺🇸
West Coast Clinical Trials (WCCT), Cypress, California, United States

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Bexagliflozin
Drug: Probenecid
Drug: Rifampin
Drug: Verapamil

First Posted Date: 2017-09-28

Last Posted Date: 2021-07-01

Lead Sponsor: Theracos

Target Recruit Count: 48

Registration Number: NCT03296800

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

Phase 3

Recruiting

Conditions: Lung Infection
Mycobacterium Avium Complex

Interventions: Drug: Clarithromycin 1000 MG
Drug: Azithromycin 250 mg
Drug: Rifampicin
Drug: Ethambutol

First Posted Date: 2017-08-02

Last Posted Date: 2023-03-22

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 424

Registration Number: NCT03236987

Locations: 🇫🇷
Saint Joseph Hospital, Marseille, France
🇫🇷
CHU Amiens Picardie, Amiens, Picardie, France

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: Rifampin
Drug: intraconazole
Drug: EDP 305

First Posted Date: 2017-07-11

Last Posted Date: 2017-11-06

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 48

Registration Number: NCT03213145

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States

A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers

Phase 1

Conditions: Tuberculosis
HIV-1-infection

Interventions: Drug: Dolutegravir
Drug: Rifampicin

First Posted Date: 2017-06-27

Last Posted Date: 2017-10-23

Lead Sponsor: St. Stephens Clinical Research

Target Recruit Count: 16

Registration Number: NCT03199690

Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: MEROPENEM 2 grams TID
Drug: MEROPENEM 1 gram TID
Drug: MEROPENEM 3 grams QD
Drug: Rifampin
Drug: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
Drug: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet

First Posted Date: 2017-06-02

Last Posted Date: 2023-07-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 112

Registration Number: NCT03174184

Locations: 🇿🇦
Task Applied Science and Stellenbosch University, Stellenbosch, South Africa

S. Aureus Decolonization in HPN Patients.

Not Applicable

Terminated

Conditions: Motility Disorder
Staphylococcus Aureus

Interventions: Drug: Doxycycline
Drug: Trimethoprim
Drug: Sulfamethoxazole/trimethoprim
Drug: Clindamycin
Drug: Clarithromycin
Drug: Ciprofloxacin
Drug: Fusidic Acid
Drug: Rifampin
Drug: Chlorhexidine
Drug: Mupirocin
Drug: Betadine

First Posted Date: 2017-06-01

Last Posted Date: 2022-05-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 63

Registration Number: NCT03173053

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark
🇳🇱
Radboud UMC, Nijmegen, Gelderland, Netherlands

and more 1 locations